THTX: Theratechnologies, Inc Price to Sales
Theratechnologies Inc. management is currently optimizing expenses to achieve stable profitability. This price-to-sales chart helps assess the asset's valuation dynamics, where 1.80 reflects the metric's latest value. The business relies on exclusive medications for treating endocrine disorders and HIV. Manufacturing capacities in North America ensure the production of niche drugs and the development of oncology therapies.
Metric breakdowns and analytics for Theratechnologies Inc (THTX)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- business debt structure and liquidity details:
Debt to Capital Theratechnologies Inc.|THTX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Theratechnologies, Inc|THTX - Company Aggregate Debts|Debts to Book Capitalization Theratechnologies Inc|THTX - Company Long-Term Liabilities|Amount of Current Liabilities Theratechnologies|Immediate Liquidity theratech.com
- earnings and market ratios statistics:
THTX - Net Profit|Future Profit Theratechnologies Inc.|THTX - P/E Multiple|Future Price to Earnings Multiple Theratechnologies, Inc.|THTX - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Theratechnologies Inc|THTX - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Theratechnologies|THTX - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months theratech.com|THTX - Earnings per share growth in current year|Expected net earnings per share growth next year Theratechnologies Inc.
- issuer revenue and sales details:
General company analysis:THTX theratech.com
When constructing a long-term portfolio, utilizing fundamental screening to identify undervalued assets is critically important. This price-to-sales multiple compares the market value of Theratechnologies Inc. (THTX) with its annual sales volume, allowing for an assessment of how effectively the company monetizes its monopoly position in HIV therapy through an analysis of this chart.
Who Theratechnologies Inc. competes with
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA: Market Cap to Revenue|Protagonist Corp - Market Cap to Sales Volume|IMVT: P/S Multiple|kiniksa.com - Market Capitalization-to-Revenue Ratio|GRFS (Grifols) - P/S Multiple|Price to Sales Adaptive Biotech ADPT|Price-to-Revenue Ratio Celldex (CLDX)|AUPH (Aurinia Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple BCRX (BioCryst)|P/S Multiple veratx.com VERA|DNTH: Market Cap to Revenue|Pharvaris NV - Market Cap to Sales Volume|ABCL: P/S Multiple|Price to Sales Tourmaline (TRML)|PGEN (Precigen, Inc.) - P/S Multiple|Market Cap to Revenue pharming.com (PHAR)|P/S Multiple NKTR|UPB (Upstream Bio, Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|IMNM: Market Cap to Revenue Ratio|GOSS - Price-to-Revenue Ratio|Price to Sales kalvista.com|Septerna (SEPN) - Price-to-Revenue Ratio|PVLA (Pieris Pharma) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Savara Corp|Price to Sales Rigel Corp RIGL|P/S Multiple ANAB|astriatx.com (ATXS) - Price-to-Revenue Multiple|P/S Multiple ENGN (enGene)|Price-to-Revenue Coefficient RAPT Therapeutics Inc. (RAPT)|Aerovate - P/S Multiple|Price to Sales Aclaris Therapeutics, Inc|Kyverna Therapeutics (KYTX) - Price-to-Revenue Ratio|TLSA - Price-to-Revenue Coefficient|Market Cap to Revenue CABA|VTYX: Market Capitalization-to-Revenue Ratio|P/S Multiple AVTX|Price-to-Revenue Coefficient Eledon Pharmaceuticals, Inc|Price-to-Revenue Ratio Agenus AGEN|CLYM: Market Cap to Revenue Ratio|Zura Bio - P/S Multiple|aTyr Pharma Inc (ATYR) - Market Cap to Revenue|ADAG (adagene.com) - Market Cap to Revenue|IMA - Price-to-Revenue Coefficient|Market Cap to Revenue STTK|EQ (Equillium Bio) - Market Cap to Sales Volume|P/S Multiple CNTB|IMUX (immunic-therapeutics.com) - Market Capitalization-to-Revenue Ratio|Atara Bio - Market Cap to Revenue|Market Cap to Sales Volume IFRX (InflaRx NV)|XFOR: Market Cap to Revenue|ACET (Adicet Bio) - Market Cap to Revenue Ratio|celularity.com (CELU) - Price-to-Revenue Ratio|Price-to-Sales Ratio INMB (INmune Bio Inc)|BRNS (Barinthus Bio) - P/S Multiple|KZR: Market Capitalization-to-Revenue Ratio|P/S Multiple SABS|P/S Multiple akaritx.com (AKTX)|Price-to-Revenue Ratio Enlivex Therapeutics Ltd. ENLV|Market Capitalization-to-Revenue Ratio QTTB|GOVX - Price-to-Revenue Ratio|Edesa Biotech Corp (EDSA) - Market Cap to Revenue|IBIO: P/S Multiple|Carisma Therapeutics Inc. (CARM) - P/S Multiple|Market Cap to Revenue XTLB|BOLT: Market Capitalization-to-Revenue Ratio|P/S Multiple HCWB|Price-to-Revenue Coefficient aptevotherapeutics.com|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|ADTX - Market Cap to Revenue|GRI - Price-to-Revenue Ratio|XORTX Therapeutics Inc (XRTX) - Market Cap to Revenue|HIND (ReShape Lifesciences) - Market Cap to Revenue|Revelation Biosciences Corp (REVB) - P/S Multiple|Price-to-Revenue Ratio Indaptus Therapeutics|Market Cap to Revenue Ratio SCNI (scinai.com)|P/S Multiple CALI|AFMD - Price to Sales|Allakos - Market Cap to Revenue|Market Cap to Sales Volume HOOK (HOOKIPA Pharma, Inc.)|IGM Bio - P/S Multiple|Market Capitalization-to-Revenue Ratio ITOS (iteostherapeutics.com)|OCEA: P/S Multiple|Price to Sales TC BioPharm (Holdings) Plc (TCBP)|Price-to-Revenue Ratio Third Harmonic Bio, Inc
